Bicara Therapeutics, Inc. (BCAX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$23.17-0.73%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · BCAX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue enrollment and execution of the FORTIFI-HN01 pivotal Phase 2/3 trial in first-line recurrent/metastatic HPV-negative head and neck squamous cell carcinoma to enable interim analysis in mid-2…
Stated as a priority in 2 of last 2 quarters. Management is on track for substantial enrollment of the FORTIFI-HN01 pivotal trial by year-end 2026 to enable an interim analysis in mid-2027. Research and development expenses increased from $24.8 million in 2025-Q2 to $45.8 million in 2026-Q2, reflecting ongoing trial costs. The trajectory matches management's stated focus on advancing this pivotal trial.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“On track for substantial enrollment of pivotal FORTIFI-HN01 study by year-end, enabling topline results from interim analysis in mid-2027.”
“Expect to be substantially enrolled by the end of the year to enable an interim analysis in mid-2027 to support potential accelerated approval.”
Start a randomized clinical study in Q3 2026 to evaluate a 12-week loading dose followed by every-three-week maintenance dosing of ficerafusp alfa in combination with pembrolizumab for 1L R/M HPV-neg…
Stated as a priority in 2 of last 2 quarters. Management planned and then initiated a randomized study in Q3 2026 to evaluate a loading and maintenance dosing regimen of ficerafusp alfa. This study is expected to yield results in time for potential accelerated approval. The trajectory shows progress from planning to initiation consistent with management's statements.
“Initiated FORTIFI-FLEX, a randomized, open-label, clinical study evaluating loading and maintenance dosing regimen with results expected by potential U.S. accelerated approval.”
“Plan to initiate a randomized clinical study evaluating a 12-week loading dose followed by maintenance dosing every three weeks in Q3 2026.”
Showcase clinical data demonstrating deep and durable responses, including three-year follow-up data from Phase 1/1b studies of ficerafusp alfa in combination with pembrolizumab in 1L R/M HPV-negativ…
Stated as a priority in 2 of last 2 quarters. Management presented extended follow-up data demonstrating an estimated 31% overall survival at three years for the 1500mg weekly dose cohort, approximately doubling survival compared to retrospective standard of care data. This clinical data delivery aligns with management's stated goal of demonstrating deep and durable responses.
“Presented extended follow-up data out to three years showing deep, durable responses and estimated 31% overall survival.”
“Presented long-term follow-up data further characterizing depth and durability of response at ASCO 2026.”
Manage financial resources to ensure existing cash, cash equivalents, and marketable securities fund operations into the first half of 2029.
Stated as a priority in 4 of last 4 quarters. The company consistently expects its cash, cash equivalents, and marketable securities to fund operations into the first half of 2029. Cash and equivalents increased from $414.8 million at 2025-Q4 to $497.3 million at 2026-Q2, supporting this runway. The trajectory is delivering on management's stated cash runway goal.
“The company expects that its existing cash, cash equivalents and marketable securities will fund operations into the first half of 2029.”
“Based on current plans, the company expects cash, cash equivalents and marketable securities will fund operations into the first half of 2029.”
“Based on current operating and development plans, the company expects cash, cash equivalents and marketable securities will fund operations into the first half of 2029.”
“The company expects that its existing cash, cash equivalents and investments will fund operations into the first half of 2029.”
Build commercial organization and readiness for potential launch of ficerafusp alfa, led by newly appointed Chief Commercial Officer.
Over the trailing year it converted 0.76x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
4 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.